Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Switzerland

Marie Skłodowska-Curie Action · Running

N2BioMetPro New-to-nature biocatalysts with metal-substituted proteins

Coordinator
Universitat Basel, Switzerland
Runs
1 September 2026 to 31 August 2028
Status
Running
EU funding
€292k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101273199

What the project is doing

In the project's own words, from its summary on CORDIS.

Transition-metal-catalysed C–H activation has revolutionised late-stage functionalisation, enabling single-step installation of functional groups into complex molecules and offering superior atom- and step-economy underpinning multibillion-dollar drug syntheses. However, current methods are limited by i) narrow substrate scope, ii) reliance on directing groups for selectivity and iii) organic solvents. To overcome these limits, N2BioMetPro will build a biocatalytic platform for selective C–H activation by engineering non-haem iron enzymes reconstituted with cobalt (NoHaeCo).

Such artificial metalloenzymes merge the catalytic power of organometallic Co(III)-based catalysts with enzymatic advantages: i) aqueous compatibility, ii) mild conditions, iii) precise active-site control and iv) directed evolution strategies to improve selectivity. The N2BioMetPro project pursues two objectives: i) assemble and identify NoHaeCo variants that catalyse abiotic C–H activations, and ii) engineer and evolve their active sites to deliver catalyst-controlled enantio- and regioselectivity, even for substrates without directing groups.

Our workflow integrates protein engineering, high-throughput screening, directed evolution, computational modelling and machine learning to obtain efficient, selective NoHaeCo biocatalysts. Target compounds include scaffolds related to Ensartinib, Sebetralstat and Etoricoxib. This interdisciplinary research combines i) biochemistry, ii) organometallic chemistry, iv) enzymology, and iv) computational science within the Thomas Ward group at the University of Basel, a world leader in artificial metalloenzymes.

The fellowship will strengthen my scientific independence and competitiveness, equipping me with cutting-edge skills at the chemistry–biology interface. By advancing catalysis aligned with the European Green Deal, the project will reinforce Europe's leadership in sustainable synthesis for the pharmaceutical, agrochemical and fine-chemical sectors.

Topics

Who is involved

OrganisationCityCountryRole
Universitat BaselBaselSwitzerlandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI